EVMN

Evommune, Inc.
CAPPED RATING

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Evommune, Inc. (EVMN) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Momentum (D-). The rating has held at C for 14 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.8 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
D-
Factor Score 0.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.2
EV / EBITDA -0.9
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -44.5%
Price Return 12M -57.4%
Catalyst Signal 0.00
Market Cap $284.5M
TTM Revenue $10.0M
Price / Sales 28.5
ROE -52.1%

Historical Factor Score Progression

Held C for 14 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.8) D+ (1.8) B- (2.9) D- (0.9) C+ (2.6) C (2.2)
2026-11-04 B- (2.9) D+ (1.7) B- (2.9) D- (0.8) C+ (2.7) C (2.2)
2026-10-28 B (3.3) D+ (1.7) B- (2.9) D- (0.8) C+ (2.7) C (2.3)
2026-10-21 B- (2.9) D+ (1.7) B- (3.0) D- (0.9) C+ (2.6) C (2.2)
2026-10-14 B- (2.9) D+ (1.7) B- (3.0) D- (1.0) C+ (2.6) C (2.2)
Page 1 of 4